Research Topics
| A B JainSummaryAffiliation: University of Rochester Country: USA Publications
| Collaborators
|
Detail Information
Publications
Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients?A Jain
Department of Surgery, Transplant Division, University of Rochester, Rochester, NY 14642, USA
Transplant Proc 37:3182-6. 2005..Valganciclovir has increasingly been used as prophylaxis against CMV after solid organ transplantation. The purpose of this study was to examine the efficacy of valganciclovir prophylaxis therapy after primary liver transplantation...- Rituximab (chimeric anti-CD20 antibody) for posttransplant lymphoproliferative disorder after solid organ transplantation in adults: long-term experience from a single centerAshokkumar B Jain
Thomas E Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, PA, USA
Transplantation 80:1692-8. 2005..Rituximab is a chimeric anti CD20 antibody, which has been used to treat PTLD with variable success. This study aims to report long-term experience with rituximab for PTLD from a single center... 
Pregnancy after liver transplantation with tacrolimus immunosuppression: a single center's experience update at 13 yearsAshokkumar B Jain
Thomas E Starzl Transplantation Institute, Division of Transplantation, Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
Transplantation 76:827-32. 2003..Tacrolimus has been increasingly used in solid-organ transplantation, and the effect of the drug on pregnancy is still of interest to clinicians. This study updates our single-center experience...- Thrombotic and nonthrombotic hepatic artery complications in adults and children following primary liver transplantation with long-term follow-up in 1000 consecutive patientsAshokkumar Jain
Department of Surgery, Division of Transplantation, University of Rochester Medical Centre, Rochester, NY 14642, USA
Transpl Int 19:27-37. 2006..3% of adults died and 69.4% grafts were lost. An overall incidence of 4.2% thrombotic and 3.2% nonthrombotic complications was observed. Rate of HAT was higher in children, but survival was better compared with adults... - Advances in hepatitis B virus infectionA B Jain
Thomas E. Starzl Transplantation Center, Pittsburgh, Pennsylvania, USA
Transplant Proc 35:342-4. 2003 - Alcoholic liver disease and transplantationA B Jain
Thomas E. Starzl Transplantation Institute, Pittsburgh, Pennsylvania, USA
Transplant Proc 35:358-60. 2003 - Effect of coadministered lopinavir and ritonavir (Kaletra) on tacrolimus blood concentration in liver transplantation patientsAshokkumar B Jain
Department of Surgery, Division of Transplantation, Thomas E Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, PA, USA
Liver Transpl 9:954-60. 2003..Great caution is required in the management of tacrolimus dosage when Kaletra is introduced or withdrawn in HIV-positive patients after liver transplantation, particularly in the presence of hepatic dysfunction... - Ribavirin levels in post liver transplant patients treated for recurrent hepatitis C viral infectionA Jain
Strong Memorial Hospital, Department of Surgery, Transplant Division, University of Rochester, Rochester, New York 14642, USA
Transplant Proc 37:3190-6. 2005..Ribavirin with pegylated interferon is the only treatment option for HCV recurrence in post-LTx patients. In clinical practice, for more than 50% of patients, ribavirin dose needs to be modified... - Use of hepatitis B core antibody-positive liver allograft in hepatitis C virus-positive and -negative recipients with use of short course of hepatitis B immunoglobulin and LamivudineA Jain
Department of Surgery, Division of Transplantation, Strong Memorial Hospital, Rochester, New York 14642, USA
Transplant Proc 37:3187-9. 2005.... - Tacrolimus for primary liver transplantation: 12 to 15 years actual follow-up with safety profileA Jain
Strong Memorial Hospital, Department of Surgery, Transplant Division, University of Rochester, Rochester, NY 14642, USA
Transplant Proc 37:1207-10. 2005..Tacrolimus has been increasingly used for liver transplantation during the last decade. The drug has immunological advantages in short- to medium-term follow-up. However, data on longitudinal follow-up are lacking... - Long-term outcome of adding mycophenolate mofetil to tacrolimus for nephrotoxicity following liver transplantationAshokkumar Jain
Department of Surgery, Transplant Division, Strong Memorial Hospital, University of Rochester, Rochester, NY 14642, USA
Transplantation 80:859-64. 2005..5% improvement at 1 year. Three patients developed renal failure. Six patients died in the follow-up period. Addition of MMF with reduced tacrolimus dose resulted in sustained improvement in renal function in 58% of patients... - Survival outcome after hepatic retransplantation for hepatitis C virus-positive and -negative recipientsA Jain
Department of Surgery, Division of Transplantation, Strong Memorial Hospital, Rochester, New York 14642, USA
Transplant Proc 37:3159-61. 2005..There is still controversy about whether such patients should undergo subsequent transplantations for HCV disease. This study compared outcomes for hepatic retransplantation performed in HCV(+) and HCV(-) recipients at a single center... - Transplantation of liver grafts from older donors: impact on recipients with hepatitis C virus infectionA Jain
Department of Surgery, Division of Transplantation, University of Rochester Medical Centre, Rochester, New York 14642, USA
Transplant Proc 37:3162-4. 2005..Hepatitis C virus (HCV) infection-related disease is presently the most common indication of LT in the United States. We studied the impact of donor age on patient and graft survivals in patients with HCV infection... - Intravenous mycophenolate mofetil with low-dose oral tacrolimus and steroid induction for live donor liver transplantationAshok Jain
Department of Surgery, Division of Transplantation, University of Rochester Medical Center, Box SURG, Rochester, NY 14642, USA
Exp Clin Transplant 3:361-5. 2005..Previously published studies have used oral formulations of MMF. In this study, we sought to examine survival, rejection, and nephrotoxicity rates using IV MMF in live donor liver transplantation (LDLT)... - Pharmacokinetics of mycophenolic acid in liver transplant patients after intravenous and oral administration of mycophenolate mofetilAshok Jain
Department of Surgery, Division of Transplantation, University of Rochester Medical Center, Rochester, NY 14642, USA
Liver Transpl 13:791-6. 2007..In conclusion, during the early postoperative period, LTx recipients have MPA exposure with oral MMF of less than half that of IV MMF. Use of IV MMF immediately post-LTx may provide an immunological advantage... - Postoperative impact of intraoperative biochemical changes at the completion of parenchymal division in living-donor liver transplantationAshok Jain
Department of Surgery, Division of Transplantation, University of Rochester Medical Center, Rochester, New York 14642, USA
Exp Clin Transplant 4:544-8. 2006.... - Characterization of CD4, CD8, CD56 positive lymphocytes and C4d deposits to distinguish acute cellular rejection from recurrent hepatitis C in post-liver transplant biopsiesAshok Jain
Department of Surgery, Division of Transplantation, University of Rochester Medical Center, Rochester, NY 14642, USA
Clin Transplant 20:624-33. 2006..Hepatitis C viral recurrence in liver allograft is almost universal, which is often difficult to distinguish from acute cellular rejection (ACR)... - HCV antibody quantitative levels in liver transplant patients: do they have any relevance in clinical practice?Ashok Jain
University of Rochester Medical Center, Division of Transplantation, Department of Surgery, Rochester, NY 14642, USA
Exp Clin Transplant 4:475-80. 2006.... - University of Wisconsin versus histidine-tryptophan-ketoglutarate for tissue preservation in live-donor liver transplantationAshok Jain
Department of Surgery, Division of Transplantation, University of Rochester Medical Center, Rochester, NY 14642, USA
Exp Clin Transplant 4:451-7. 2006..We therefore sought to examine the hepatic function of live-donor liver transplantation allografts preserved in University of Wisconsin solution as compared with those preserved in histidine-tryptophan- ketoglutarate solution... 
Potential immunological advantage of intravenous mycophenolate mofetil with tacrolimus and steroids in primary deceased donor liver transplantation and live donor liver transplantation without antibody inductionAshokkumar Jain
Department of Surgery, Division of Solid Organ Transplantation, University of Rochester Medical Center, Rochester, NY 14642, USA
Liver Transpl 14:202-9. 2008..All patients responded to steroid therapy. None of the patients required any antibody preparation. In conclusion, IV MMF with tacrolimus and steroids is useful and required antirejection therapy in 6.1% of liver transplant recipients...- Pharmacokinetics of tacrolimus in living donor liver transplant and deceased donor liver transplant recipientsAshok Jain
Department of Surgery, Division of Solid Organ Transplant, University of Rochester Medical Center, Rochester, NY, USA
Transplantation 85:554-60. 2008..AIM.: The aim of the present study is to compare the dosage, concentration and pharmacokinetics parameters of tacrolimus between LDLT and deceased donor liver transplant (DDLT) recipients... - Response to antiviral therapy in liver transplant recipients with recurrent hepatitis C viral infection: a single center experienceAshok Jain
Department of Surgery, Division of Solid Organ Transplantation, University of Rochester Medical Center, Rochester, NY, USA
Clin Transplant 24:104-11. 2010..Recurrence of hepatitis C virus (HCV) in hepatic allograft is a major concern after successful liver transplant (LTx)... - Pharmacokinetics of mycophenolic acid in live donor liver transplant patients vs deceased donor liver transplant patientsAshok Jain
University of Rochester Medical Center, Department of Surgery, Division of Solid Organ Transplantation, Rochester, NY 14642, USA
J Clin Pharmacol 48:547-52. 2008..These observations point to the need to use a lower dosage (approximately 30%) of mycophenolate mofetil in live donor liver transplant patients compared with deceased donor liver transplant patients... - Kidney transplantation for end-stage renal failure in liver transplant recipients with hepatitis C viral infectionE P Molmenti
Thomas E Starzl Transplantation Institute and the Division of Transplantation Surgery, University of Pittsburgh, Pennsylvania 15213, USA
Transplantation 71:267-71. 2001..KTx should be offered for end-stage renal failure after LTx, even in the presence of HCV infection, to individuals with stable liver function and no signs of liver failure... - Living donor liver transplantation: ethics and safetyB Eghtesad
Thomas E. Starzl Transplantation Institute, Pittsburgh, Pennsylvania, USA
Transplant Proc 35:51-2. 2003 - A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone and mycophenolate mofetil in primary adult liver transplantation: a single center reportA Jain
University of Pittsburgh, Thomas E. Starzl Transplantation Institute, 4th Floor Falk Medical Building, 3601 Fifth Avenue, Pittsburgh, PA 15213, USA
Transplantation 72:1091-7. 2001..However, the complex nature of LTx patients and their posttransplantation course prevents the routine application of MMF... - Survival of liver transplant patients coinfected with HIV and HCV is adversely impacted by recurrent hepatitis CM E De Vera
Thomas E Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
Am J Transplant 6:2983-93. 2006..Hepatitis C is a major cause of graft loss and patient mortality in coinfected patients undergoing LTx... - Pediatric liver transplantation in 808 consecutive children: 20-years experience from a single centerA Jain
Children's Hospital of Pittsburgh and the Thomas E. Starzl Transplantation Institute, Dept. of Surgery, School of Pharmaceutical Sciences, University of Pittsburgh Medical Center, 3705 Fifth Avenue, Pittsburgh, PA 15213, USA
Transplant Proc 34:1955-7. 2002 - A pilot trial of tacrolimus, sirolimus, and steroids in renal transplant recipientsR Shapiro
Thomas E. Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
Transplant Proc 34:1651-2. 2002 - Conversion from cyclosporin to tacrolimus in paediatric liver transplant recipientsG V Mazariegos
Thomas E Starzl Transplantation Institute, Children s Hospital of Pittsburgh, University of Pittsburgh Medical Center, PA 15213, USA
Paediatr Drugs 3:661-72. 2001..Avoidance of cyclosporin-related toxicity and minimisation of corticosteroid therapy may further improve patient compliance to drug therapy... - P-glycoprotein (P-gp) is upregulated in peripheral T-cell subsets from solid organ transplant recipientsV S Donnenberg
Department of Medicine, School of Pharmacy, University of Pittsburgh, Pennsylvania 15213, USA
J Clin Pharmacol 41:1271-9. 2001.... - Pharmacokinetics of mycophenolic acid after mycophenolate mofetil administration in liver transplant patients treated with tacrolimusA Jain
School of Pharmacy, University of Pittsburgh, Pennsylvania 15261, USA
J Clin Pharmacol 41:268-76. 2001..Changes in albumin appear to partially contribute to the variations in the pharmacokinetics of MPA in liver transplant patients... - Change in oral absorption of tacrolimus in a liver transplant recipient after reversal of jejunoileal bypass: case reportM Kelley
Department of Pharmacy, Division of Transplantation, University of Rochester Medical Center-Strong Memorial Hospital, Rochester, New York 14642, USA
Transplant Proc 37:3165-7. 2005..CONCLUSION: After JIB reversal, the patient showed higher systemic levels of tacrolimus and required lower steady-state doses. It is therefore imperative that such patients be monitored closely to avoid tacrolimus-related toxicity... - Reasons for long-term use of steroid in primary adult liver transplantation under tacrolimusA Jain
Department of Surgery, Thomas E. Starzl Transplantation Institute, Pittsburgh, Pennsylvania, USA
Transplantation 71:1102-6. 2001..Although the use of other immunosuppressive agents may reduce the rate of reintroduction of steroid, long-term sustained freedom from steroid may not be possible in all patients under tacrolimus secondary to these conditions... - An analysis of early renal transplant protocol biopsies--the high incidence of subclinical tubulitisR Shapiro
University of Pittsburgh, Thomas E Starzl Transplantation Institute, PA 15213, USA
Am J Transplant 1:47-50. 2001..This suggests that the true incidence of rejection may be higher than is clinically appreciated... - Almost total absence of chronic rejection in primary pediatric liver transplantation under tacrolimusA Jain
Children's Hospital of Pittsburgh and the Thomas E. Starzl Transplantation Institute, Department of Surgery, School of Pharmaceutical Sciences, University of Pittsburgh Medical Center, 3601 Fifth Avenue, Pittsburgh, PA 15213, USA
Transplant Proc 34:1968-9. 2002 - Occult nonhematopoietic malignancies present at autopsy in solid organ transplant patients who died within 100 daysM S Torbenson
Department of Pathology, University of Pittsburgh Medical Center, Pennsylvania, USA
Transplantation 71:64-9. 2001.... - Reasons why some children receiving tacrolimus therapy require steroids more than 5 years post liver transplantationA Jain
Thomas E. Starzl Transplantation Institute, Department of Surgery and Department of Pharmaceutical Sciences, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA
Pediatr Transplant 5:93-8. 2001..The concomitant use of other non-steroidal immunosuppressive agents with tacrolimus may further reduce the dose and rate of steroid use... - Clinical utility of monitoring tacrolimus blood concentrations in liver transplant patientsR Venkataramanan
Department of Pharmaceutical Sciences, Pathology, and Surgery, University of Pittsburgh, Pennsylvania 15261, USA
J Clin Pharmacol 41:542-51. 2001.... - Does tacrolimus offer virtual freedom from chronic rejection after primary liver transplantation? Risk and prognostic factors in 1,048 liver transplantations with a mean follow-up of 6 yearsA Jain
Departments of Surgery, Thomas E Starzl Transplantation Institute, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA
Liver Transpl 7:623-30. 2001..05) was the only factor found to be significant between patients who had graft loss versus those who recovered... - Primary tacrolimus (FK506) therapy and the long-term risk of post-transplant lymphoproliferative disease in pediatric liver transplant recipientsT V Cacciarelli
Department of Surgery, Thomas E Starzl Transplantation Institute, University of Pittsburgh School of Medicine, 3601 Fifth Ave, Pittsburgh, PA 15213, USA
Pediatr Transplant 5:359-64. 2001..Primary tacrolimus use in pediatric LTx has a long-term risk of PTLD approaching 15%, with the majority of episodes (78%) occurring in the first 2 yr, suggesting that intense EBV surveillance should occur early post-transplantation... - The Pittsburgh randomized trial of tacrolimus compared to cyclosporine for hepatic transplantationJ J Fung
Pittsburgh Transplantation Institute, University of Pittsburgh Medical Center, PA, USA
J Am Coll Surg 183:117-25. 1996..8 percent of the patients receiving cyclosporine showing freedom from rejection at one year (p = 0.003, likelihood ratio test). Survival of patients over the course of the study was virtually the same in the two groups... - De novo malignancies after liver transplantation: a major cause of late deathJ J Fung
Division of Transplantation Surgery, the Thomas E Starzl Transplantation Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
Liver Transpl 7:S109-18. 2001..5. An increased incidence of de novo cancers in chronically immunocompromised liver transplant recipients demands careful long-term screening protocols to help facilitate diagnosis at an earlier stage of disease... - Use of a high-risk alcohol relapse scale in evaluating liver transplant candidatesA DiMartini
Department of Psychiatry and the Thomas E Starzl Transplant Institute at the University of Pittsburgh Medical Center, Pennsylvania, USA
Alcohol Clin Exp Res 24:1198-201. 2000..We chose to investigate the use of the High-Risk Alcohol Relapse (HRAR) scale in our transplant population in the hope that it would improve our ability to identify and follow patients at highest risk for alcohol relapse... - Establishing pharmacokinetic bioequivalence of valganciclovir oral solution versus the tablet formulationM D Pescovitz
Department of Surgery, Indiana University, Indianapolis, Indiana 46202 5253, USA
Transplant Proc 39:3111-6. 2007..With the demonstration of bioequivalence and no differences in the incidence of adverse effects, it will be possible to interchangeably use the oral formulation... - Living-donor liver transplantation in the United States: identifying donors at risk for perioperative complicationsS Patel
Division of Transplantation, Department of Surgery, University of Rochester Medical Center, Rochester, NY, USA
Am J Transplant 7:2344-9. 2007..Living liver donation is currently performed with a low risk of major morbidity. Use of administrative data represents an important tool to facilitate a better understanding of donor risk factors... - Allograft liver biopsy in patients with Epstein-Barr virus-associated posttransplant lymphoproliferative diseaseP Randhawa
Division of Transplantation Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
Am J Surg Pathol 25:324-30. 2001..Rejection may be treated even if EBV is concurrently present. Long-term graft is suboptimal, because low immunosuppression results in a tendency to develop chronic rejection... - Real-time monitoring of acute liver-allograft rejection using the Banff schemaA J Demetris
Department of Pathology, Division of Transplantation, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA
Transplantation 74:1290-6. 2002..The Banff schema is the internationally accepted standard for grading acute liver-allograft rejection, but it has not been prospectively tested... - Alcohol use following liver transplantation: a comparison of follow-up methodsA DiMartini
Department of Psychiatry, University of Pittsburgh Medical Center, PA, USA
Psychosomatics 42:55-62. 2001..With this type of accuracy, risk factors can be identified and alcohol use can be compared with alcohol-related morbidity posttransplant... - Nephrogenic systemic fibrosis among liver transplant recipients: a single institution experience and topic updateM Maloo
Division of Transplantation, Department of Surgery, University of Rochester Medical Center, Rochester, New York, USA
Am J Transplant 6:2212-7. 2006..Early recognition and implementation of aggressive physical therapy appear to have the greatest impact on halting its progression... - Pregnancy after kidney and kidney-pancreas transplantation under tacrolimus: a single center's experienceAshokkumar B Jain
Thomas E Starzl Transplantation Institute, UPMC Montefiore, Pittsburgh, PA, USA
Transplantation 77:897-902. 2004..The aim of the present report is to examine the outcome of pregnancies under tacrolimus after kidney transplantation (KTx) and simultaneous kidney-pancreas transplantation (SPKTx)...